Quantitation of Glymphatic Functioning in Sleep and Meditative States
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04506892 |
Recruitment Status :
Recruiting
First Posted : August 10, 2020
Last Update Posted : April 22, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson Disease Sleep | Behavioral: Meditation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Masking Description: | no masking is used in this protocol |
Primary Purpose: | Basic Science |
Official Title: | Quantitation of Glymphatic Functioning in Sleep and Meditative States |
Actual Study Start Date : | February 1, 2021 |
Estimated Primary Completion Date : | July 2026 |
Estimated Study Completion Date : | July 2027 |

Arm | Intervention/treatment |
---|---|
Experimental: Adept Meditators
Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
|
Behavioral: Meditation
meditation |
- CSF flow change [ Time Frame: baseline to 24 hours ]Using MRI to assess the change in CSF flow in awake, sleep deprived, and meditative states
- EEG changes [ Time Frame: baseline to 24 hours ]Looking at brain wave changes before and after intervention in Alpha, Beta, and Delta waves associated with light to deep sleep. The lowest bandwidth for alpha waves is 8 while the highest is 12. The lowest bandwidth for Beta waves is 13 Hz while the highest is 30 Hz. The lowest bandwidth for Delta waves is .4 Hz and the highest is 4 Hz.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Ages 14-45
- "Adept meditator status"
Exclusion Criteria:
- Any non-MR compatible material implant, or contraindication to MR scanning
- Claustrophobia or inability to lie still for prolonged periods of time
- Participants with a recent (less than 2 months) infection, tattoo, or wound
- No consumption of stimulants or alcohol within 12 hours of the study visit
- clinical diagnosis of any major neurological or psychological condition
- Taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, MAO inhibitors

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04506892
Contact: Daniel Claassen, MD | 6153226103 | daniel.claassen@vumc.org | |
Contact: Maria Garza, MS | maria.e.garza@vumc.org |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37212-3160 |
Principal Investigator: | Daniel Claassen, MD | Vanderbilt University Medical Center |
Responsible Party: | Daniel Claassen, Associate Professor, Vanderbilt University Medical Center |
ClinicalTrials.gov Identifier: | NCT04506892 |
Other Study ID Numbers: |
RFA-AT-21-001 |
First Posted: | August 10, 2020 Key Record Dates |
Last Update Posted: | April 22, 2022 |
Last Verified: | April 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
glymphatic system meditation |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |